Treatments with poly(ADP-ribose) polymerase (PARP) inhibitors have shown success in cancers that are HR-deficient, such as BRCA-deficient ovarian, breast, pancreatic, and prostate cancer, which has led to the approval of four different PARP inhibitors and many others still in clinical trials [148]. This evidence concerns the gene PARP1 and cancer.